

Serial No. 09/966,493

Claim 1 (currently amended): A swallowable immediate release tablet comprising at least 60 weight % of an active ingredient and a powdered wax having an melting point greater than about 90° C and a particle size in the range of about 5 to about 100 microns, said swallowable immediate release tablet meeting the USP dissolution specifications for immediate release tablets containing said active ingredient.

Claim 2 (previously presented): The tablet of claim 1, wherein the active ingredient is selected from the group consisting of acetaminophen, ibuprofen, calcium carbonate, magnesium hydroxide, magnesium carbonate, magnesium oxide, aluminum hydroxide, mixtures thereof, and pharmaceutically acceptable salts thereof.

Claim 3 (previously presented): The tablet of claim 1, wherein the wax is selected from the group consisting of linear hydrocarbons, microcrystalline wax, and mixtures thereof.

Claim 4 (previously presented): The tablet of claim 1 prepared by direct compression.

Claim 5 (previously presented): The tablet of claim 1 which is substantially free of water-soluble, non-saccharide polymeric binders.

Claim 6 (previously presented): The tablet of claim 1, which is substantially free of hydrated polymers.

Claim 7 (previously presented): The tablet of claim 1 further comprising at least one outer coating.

Claim 8 (previously presented): The tablet of claim 7, wherein the outer coating comprises a material selected from the group consisting of gelatin, isomalt, monosaccharides, disaccharides, polysaccharides such as starch, cellulose derivatives,

Serial No. 09/966,493

shellacs, polyhedric alcohols such as xylitol, mannitol, sorbitol, maltitol, erythritol, and polyalkylene glycols.

Claim 9 (previously presented): The tablet of claim 1 comprising up to about 20 weight percent wax.

Claim 10 (previously presented): The tablet of claim 1 further comprising an excipient selected from the group consisting of disintegrants, flow aids, and optionally lubricants.

Claim 11 (previously presented): The tablet of claim 1 further comprising an insert disposed within tablet.

Claim 12 (previously presented): The tablet of claim 11, wherein the insert comprises additional active ingredient.

Claim 13 (previously presented): The tablet of claim 12, wherein the additional active ingredient has a different release profile from the active ingredient in the tablet.

Claim 14 (previously presented): The tablet of claim 12, wherein the amount of additional active ingredient is from about 0.1 to about 30 mg.

Claim 15 (previously presented): The tablet of claim 12, wherein the additional active ingredient is selected from the group consisting of loratadine, fexofenadine, cetirizine, chlorpheniramine, brompheniramine, diphenhydramine, pseudoephedrine, cyproheptadine, montelukast, loperamide, famotidine, dexamethasone, hydrocortisone, cyclobenzaprine, alendronate, hydrochlorthiazide, rofecoxib, indomethacin, ketoprofen, meloxicam, piroxicam, lovastatin, atorvastatin, pravastatin, simvastatin, finasteride, and pharmaceutically acceptable salts, esters, and mixtures thereof.

Claim 16 (cancelled)

Claim 17 (currently amended): A swallowable immediate release tablet comprising at least 60 weight percent of an active ingredient and a powdered wax having a particle size is in the range of about 5 to about 100 microns that is selected from the group consisting of shellac wax, paraffin-type waxes, polyethylene glycol, and mixtures thereof; wherein said swallowable tablet is prepared by direct compression.

Claim 18 (currently amended): A swallowable immediate release tablet comprising at least 60 weight percent of an active ingredient and a powdered wax having a particle size is in the range of about 5 to about 100 microns that is selected from the group consisting of shellac wax, paraffin-type waxes, polyethylene glycol, and mixtures thereof; wherein said swallowable tablet is substantially free of water-soluble, non-saccharide polymeric binders.

Claim 19 (currently amended): A swallowable immediate release tablet comprising at least 60 weight percent of an active ingredient and a powdered wax having a particle size is in the range of about 5 to about 100 microns that is selected from the group consisting of shellac wax, paraffin-type waxes, polyethylene glycol, and mixtures thereof; wherein said tablet is substantially free of hydrated polymers.

Claim 20 (previously presented): The tablet of claim 17, wherein said active ingredient is in its native crystalline form.